Site no longer supporterd

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site. We expect to close the site down by December 2016.

You are here

The pharmacological toolbox for the treatment of patients with alcohol dependence

  • Neurobiology and pharmacological treatments

    Part 1 of presentation The pharmacological toolbox for the treatment of patients with alcohol dependence

    We know where the functions are disturbed, and we know which brain structures are involved more or less – we know most of this from animal research but also lately of course from the neuroimaging studies. We also have some ideas about which neurotransmitters are involved, and we know that we can start to develop medications.

  • A spectrum of available treatments

    Part 2 of presentation The pharmacological toolbox for the treatment of patients with alcohol dependence

    A range of new pharmacological treatments is available with different modes of action and for different goals - for abstinence and reduced drinking. People sometimes start with reduced drinking and then move to abstinence, or they start with abstinence as their treatment goal and then move to reduced drinking. We should be flexible about this, because it is not written in stone.

  • Focus on nalmefene - part one

    Part 3 of presentation The pharmacological toolbox for the treatment of patients with alcohol dependence

    A brief explanation of the pharmacokinetics of nalmefene, and presentation of results from three large randomised controlled trials conducted in patients with alcohol dependence, comparing nalmefene with placebo.

  • Focus on nalmefene - part two

    Part 4 of presentation The pharmacological toolbox for the treatment of patients with alcohol dependence

    Standardised effect sizes for nalmefene compare to those of other medications like antipsychotics and antidepressants. Nalmefene has a good safety profile; the most frequent treatment-emergent adverse events are transient and patients need to be informed of these to increase compliance.

E-Alert

Subscribe to our E-Alert to stay informed of all new content as it's published on this platform.

Share

Notify your friends and contacts about this Progress in Mind Resource Centre, with free access to excellent content.

 

 

 

Search this site

Search form

This Resource Centre has been made possible by Lundbeck. Note that Lundbeck has no editorial control or influence over the content of this Resource Centre. The Resource Centre and all content therein have been subject to an independent editorial review.